Poor clinical outcome of relapsed/refractory diffuse large B-cell                    lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine,                    and rituximab

Masuho Saburi; Masanori Sakata; Yousuke Kodama; Keiichi Uraisami; Hiroyuki Takata; Yasuhiko Miyazaki; Junpei Wada; Shogo Urabe; Eiichi Ohtsuka

doi:10.3960/jslrt.23017

Journal of Clinical and Experimental Hematopathology

Online ISSN : 1880-9952
Print ISSN : 1346-4280
ISSN-L : 1346-4280

Short Communication

Poor clinical outcome of relapsed/refractory diffuse large B-cell lymphoma with MYC translocation treated with polatuzumab vedotin, bendamustine, and rituximab

Masuho Saburi , Masanori Sakata, Yousuke Kodama, Keiichi Uraisami, Hiroyuki Takata, Yasuhiko Miyazaki, Junpei Wada, Shogo Urabe, Eiichi Ohtsuka

Author information

Keywords: diffuse large B-cell lymphoma, polatuzumab vedotin, bendamustine, MYC translocation

JOURNAL OPEN ACCESS

2023 Volume 63 Issue 3 Pages 201-204

DOI https://doi.org/10.3960/jslrt.23017

Browse “Advance online publication” version

Details

Article 1st page

Content from these authors

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
https://creativecommons.org/licenses/by-nc-sa/4.0/deed.ja

Favorites & Alerts

Corresponding author

Register with J-STAGE for free!